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Gelatin zymographyIschemic stroke (IS) outcome predictors include clinical features, biochemical parameters and some risk factors.
The relations between twomain players in the ischemic brain, MMPs and HMGB1, were estimated in the plasma
of ischemic stroke patients stratiﬁed according to the Glasgow Outcome Scale and the Oxfordshire Community
Stroke Project classiﬁcation. IS patients exhibited higher plasma concentration of MMP-9 and the inﬂammatory
cytokine HMGB1 compared with healthy controls. A full-blown correlation between MMP-9 activation and
increased plasma MMP-9 concentration was observed in case of IS patients. A similar activity of MMP-2 and
MMP-12 was characteristic of healthy volunteers and IS patients. In patients with ischemic stroke increased
plasma levels of MMP-9 and HMGB1 are associated with a poor functional outcome and are signiﬁcantly
correlated with each other (P = 0.0054). We suggest that diagnostic beneﬁts will be obtained if plasma
HMGB1 levels are measured for IS patients in addition to MMP-9.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
The pathogenesis of ischemic stroke is highly complex, involving
inﬂammation, hemostasis, neuronal and glial injury.Matrixmetallopro-
teinases (MMPs) are markers, amongst others, for the pathological IS
processes, showing a signiﬁcant association between their levels and
the pathology. MMPs can broadly target almost all components of the
mammalian central nervous system [1]. MMPs attack the extracellular
matrix (ECM) around the blood vessels as well as the matrix around
neurons, facilitating neural cell death. Several MMPs, especially MMP-
9, have been implicated in the regulation of blood–brain barrier (BBB)
permeability and function during ischemic stroke [2]. In the early
phase (hours to days) after cerebral ischemia, MMPs disrupt the
blood–brain barrier, leading to BBB leakage, leukocyte inﬁltration,
brain edema, and hemorrhage [3].
A number of reports have indicated that the High-mobility group
box 1 protein (HMGB1) plays the role of a danger signal in the ischemic
brain. It is involved in the pathogenesis of a variety of non-infectious
inﬂammatory conditions including sterile injures generated as a result
of ischemia/reperfusion and stroke [4].
HMGB1 is a multipotent protein. It is generally accepted that it lives
a double life: as an architectural transcription factor in the nucleus andikova).as an extracellular signal. HMGB1 is passively released from all nucleat-
ed cells during necrosis and it signals to neighboring cells of ongoing
damage [5]. Although apoptotic cells produce less HMGB1 than do ne-
crotic cells, macrophage engulfment of apoptotic cells leads to greater
HMGB1 release. HMGB1 can also be actively released from immune
cells, including macrophages, monocytes, neutrophils, and platelets,
and also from endothelial cells [6]. Macrophages release HMGB1 in
response to various stimuli including oxidative stress. As an actively
secreted protein from macrophages, HMGB1 can stimulate inactive
immune cells to produce cascades of cytokines.
Ischemic injury causes tissue damage and around the ischemic core,
inﬂammatory processes cause further damage in the penumbra.
HMGB1 is rapidly released due to tissue damage and it is actively secret-
ed around the ischemic core by activated immune cells. The HMGB1
content is high in neurons, Schwann cells, endothelial cells, monocytes
and macrophages under these conditions [7]. All these cells can be
source of extracellularHMGB1 after acute ischemic stroke andmeasure-
ments of HMGB1 in blood at acute ischemic stroke can be considered as
a noninvasive tool for monitoring the condition.
Matrix metalloproteinases are secreted into the blood by a variety of
connective tissue and proinﬂammatory cells, including ﬁbroblasts, oste-
oblasts, endothelial cells, macrophages, neutrophiles and lymphocytes
[8].
The main objectives of this study are to test whether the proﬁles of
matrix metalloproteinases MMP-2, MMP-9, MMP-12 and the extracel-
lular cytokine HMGB1 change in the plasma of patients during the
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whether they can provide prognostic information for stroke severity
and pathophysiology. In addition we investigate the relationship be-
tween MMP-9 and HMGB1 as a functional outcome of IS. An evaluation
of this relationship highlights HMGB1 and MMP-blocking agents as
potential therapeutic tools for neuroprotection following IS.
2. Materials and methods
2.1. Clinical study
Case subjects were selected from acute stroke patients admitted to
the Sarajishvili Institute of Neurology and Neurosurgery (SINN). 42 eli-
gible subjects (22 males and 20 females, average age of 69 ± 15 years)
were selected from 70 patients with suspected acute stroke admitted to
Clinical or Critical Care departments of the SINN. Reasons for exclusion
included: ﬁnal diagnoses other than stroke (7 cases), admission after
24 h of stroke onset (4 cases), hemorrhagic stroke (10 patients)
and patients' refusal to participate in the study (7 cases). All study
subjects underwent the following investigations: detailed neurological
examination (special stroke scales for evaluating the stroke severity
and functional state were used according to the study protocol), CT,
extracranial dopplerography, EKG and detailed laboratory work-up
including routine blood and urine analysis, coagulation tests, venous
hematocrit and routine blood biochemistry tests (glucose and total cho-
lesterol). Patients were clinically evaluated using the Glasgow Outcome
Scale (GOS), the Glasgow Coma Scale (GCS), the Barthlet–Rankin Scale
and the Allen Scale. In addition, patients were stratiﬁed according to
the Oxfordshire Community Stroke Project (OCSP) classiﬁcation. The
OCSP classiﬁcation is widely used for stroke pathophysiology classiﬁca-
tion. This classiﬁcation divides cerebral infarction into four categories:
total anterior circulation infarction (TACI), partial anterior circulation
infarction (PACI), lacunar infarction (LACI), and posterior circulation
infarction (POCI). In our study, there were insufﬁcient numbers of
POCI cases for statistical analysis.
Healthy individuals were selected randomly from outpatients
paying visits to the Polyclinic of the SINN and healthy donors were
selected from the Blood Bank of Jo Ann's Medical Center (Tbilisi,
Georgia). Controls were people without acute stroke/history of stroke
and without current acute or chronic inﬂammatory illness. This study
includes plasma samples from 32 healthy individuals (15 males and
17 females; average age of 63 ± 20 years). Blood samples were drawn
in sterile tubes and then centrifuged for the further analyses of plasma.
The study protocol was approved by the local ethics committee, and
written informed consent was obtained from each participant or their
relatives before inclusion in the study.
2.2. Gelatin zymography
Substrate zymography is the most sensitive assay for MMP detec-
tion. Plasma samples were analyzed on 12% (w/v) acrylamide gels con-
taining 1.5 mg/ml gelatin in the presence of sodium dodecyl sulphate
(SDS) under non-reducing conditions, in accordance with Gerlach
et al., [9] with some modiﬁcations. After electrophoresis the gels were
washed in the Renaturing Buffer (50 mM Tris–HCl, pH 7.5; 2.5% w/v
Triton X-100) to remove the SDS. Overnight incubation of the gel at
37 °C in the Developing Buffer (50 mM Tris–HCl buffer, pH 7.5, 0.2 M
NaCl, 5 mmol/l CaCl2, and 0.2% Brij 35) allowed the reactivated enzyme
to degrade the copolymerized substrate. Subsequently, the gels were
stained with 0.05% Coomassie Brilliant Blue R-250 and the areas
where the gelatin substrate has been degraded by gelatinases develop
into white lines on a dark background. The loading corresponded to
1 μl of plasma. Gelatinase activity was conﬁrmed as MMP (Zn2+- and
Ca2+-dependent endopeptidases) since it was inhibited by 20 mM
1,10-phenanthroline, a zinc chelator, and by 5 mM EDTA, the broad-
spectrum metal chelator (data not shown).2.3. Western blot method for the detection of total MMP-12 in plasma
Western blotting with anti-MMP-12 antibodies (Cat.-No.: M-0807
Sigma, USA) was used to detect plasma MMP-12 in ischemic stroke pa-
tients and in normal plasma. Western blots were prepared from total
plasma protein samples diluted x1:25 in Laemmli loading buffer and
separated on 12% (w/v) SDS-polyacrylamide gels (normalized to 80 μg
per lane) and blotted onto nitrocellulose Hybond ECL membrane
(Amersham, USA). Membranes were blocked with 5% (w/v) Marvel in
1×PBS for 1 h, then washed with 1×PBS and 0.1% Tween 20 and ﬁnally
incubated with diluted antibodies (IgG) against human MMP-12. The
primary antibodies (1:1000) were developed for 1 h at RT, followed
by secondary goat anti-rabbit IgG (1:1000) (Cat.-No.: A-9169 Sigma,
USA) for 1 h at RT. After further washing with 1×PBS and 0.1% Tween
20, chemiluminescent detection was performed using the X-ray ﬁlm
(Kodak, USA). To be sure that the lines correspond to MMP-12, the
human MMP-12 (Cat.-No.: ab131994, Abcam, UK) and the ColorBurst
electrophoresis marker (M.W. 8000–220,000) (Cat.-No.: C1992 Sigma,
USA) were used.2.4. ELISA method for the quantiﬁcation of MMP-9 and HMGB1 in plasma
MMP-9 and HMGB1 assay ELISA kits (Cat.-No.: BE59491 and
ST51011 respectively, IBL International, Germany) based on monoclo-
nal antibodies to human MMP-9 and polyclonal antibodies to HMGB1
were used to quantify MMP-9 and HMGB1 in plasma, following the
manufacturer's instructions. The human MMP-9 levels ranged between
8.0 and 90.0 ng/ml for plasma samples from the apparently healthy
donors. HMGB1concentration in plasma of healthy donors is less than
1.4 ng/ml.2.5. Methods of analysis
All values are expressed as means and medians by using Origin for
Windows, version OriginPro8, and were analyzed using the Mann–
Whitney U test (two-tailed). Correlations between variables were
determined by Spearman rank test and Pearson rank test. Spearman
rank correlation coefﬁcient (rs) provides a measure of how closely two
sets of rankings agree with each other. Pearson correlation coefﬁcient
(rp) is a measure of the strength of the association between the two
variables. A P value b0.05 was taken to be of statistical signiﬁcance;
a P value b0.01 was taken to indicate a signiﬁcant difference; and a
P value ≥0.05 was taken not to be of statistical signiﬁcance.3. Results
3.1. MMP-9 and MMP-2 in plasma following ischemic stroke
MMPs are synthesized and secreted as inactive proenzymes (zymo-
gens) that subsequently become proteolytically cleaved and activated.
The visualization of the pro-MMP-9 (MW= 92 kDa) and active MMP-
9 (MW = 87 kDa) forms is presented in Fig. 1. Both forms of MMP-9
were present in the blood samples of control and IS patients. However,
the MMP-9 zymograms show that there are signiﬁcant differences in
the ratio of pro-active and active MMP-9 forms in ischemic stroke
patients compared to the control samples. In the case of IS patients
the active MMP-9 form is increased signiﬁcantly. As concerns the
healthy volunteer controls, only in ﬁve studied subjects was an increase
of the active MMP-9 form observed. As follows from Fig. 1, MMP-2 is
present in pro-active form (MW = 72 kDa) in all cases. Activation of
MMP-2 (to give an active form with MW= 67 kDa) was not observed.
The same proﬁle of MMP-2 was observed in samples from healthy
volunteers and from IS patients.
12% PAAG/0.15% Gelatin
IS11  IS3 IS27 IS18 IS17  IS13 C7 C16 M
MMP-9 ng/ml 428 101 585 235 535 269 44 66.5
Marker
MMP-9
Marker
MMP-2
Active MMP-9
Pro-MMP-9
Pro-MMP-2
Fig. 1. Representative zymogram of the plasma sample corresponding to healthy volunteers (C—controls), ischemic stroke patients (IS), and marker (M). The positions of pro-MMP-9,
activatedMMP-9, and pro-MMP-2 as the achromatic zones are indicated by arrows. Amixture ofMMP-9 andMMP-2 containing gelatinasewas used as amarker. The loading corresponds
to 1 μl of plasma, normalized to the concentration of total plasma proteins.
1381N. Sapojnikova et al. / Biochimica et Biophysica Acta 1842 (2014) 1379–13843.2. MMP-9 concentration in plasma following acute ischemic stroke.
Relation to the clinical outcome and to the cerebral infarction category
MMP-9 plasma concentration, determined using monoclonal anti-
bodies to human MMP-9, quantitatively estimates all forms of MMP-9
present in plasma: inactive, active and inhibited by forming a complex
with the speciﬁc tissue inhibitor of metalloproteinases (TIMP).
Neurological impairment after IS refers to a broad group of disorders
in which the central nervous system does not function properly and
leads to some form of physical and mental problems. We classiﬁed
patients according to GOS and compared theMMP-9 plasma concentra-
tion in each category with the control. GOS evaluates clinical outcome
on a scale from 1 to 5: scale point one constitutes the worst outcome
(death), whereas point 5 represents the best score (recovery). The
clinical outcome was evaluated at hospital discharge and one monthH
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Fig. 2. Plasma levels ofMMP-9 andHMGB1 in controls and ischemic stroke patients stratiﬁed acc
outcome (death and functional decline); IS (4)—Fairly good outcome (moderate disability)
circulation infarction (TACI), partial anterior circulation infarction (PACI), and lacunar infarcti
to be of statistical signiﬁcance; a P value b0.01 is taken to indicate a signiﬁcant difference; andafter ischemic stroke. The data presented in Fig. 2A shows that the
negative outcome is signiﬁcantly correlated with the increased MMP-
9 concentration in plasma, estimated 24 h after IS onset.
TheMMP-9 plasma concentration in each category of the Oxfordshire
Community Stroke project classiﬁcation was also compared with the
controls (Fig. 2B). The total anterior circulation infarction (TACI) catego-
ry is likewise signiﬁcantly correlated with the increased MMP-9 con-
centration in plasma estimated 24 h after IS onset.3.3. MMP-9 concentration and activation at ischemic stroke
A correlation between MMP-9 activation and increased plasma
MMP-9 concentration was observed for the IS patients in our study.
The increased MMP-9 concentration observed for some controlB
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ording to GOS and theOCSP classiﬁcation. GlasgowOutcome Scale (GOS): IS (1 to 3)—Poor
; and IS (5)—Good outcome (recovery). The OCSP classiﬁcation includes: total anterior
on (LACI). Values are analyzed using the Mann–Whitney U test. A P value b0.05 is taken
a P value ≥0.05 is taken not to be of statistical signiﬁcance.
Table 1
Characteristics of MMP-9 activation in the plasma of selective controls (C) and ischemic stroke patients (St) within the ﬁrst 24 h of IS onset.
Controls
(healthy volunteers)
MMP-9 ng/ml
(9–80 ng/ml norm)
Active MMP-9 Ischemic stroke
(patients)
MMP-9 ng/ml
(9–80 ng/ml norm)
Active MMP-9
C2 32.9 − St2 241 +
C6 35.9 − St3 101 +
C7 44 − St4 551 +
C9 151 + St7 172 +
C10 134 + St8 71.3 −
C12 108 − St9 25.7 −
C13 131 − St11 428 +
C14 161 + St13 269 +
C15 89.3 − St14 51 −
C16 66.5 − St15 49 −
C17 143 + St17 535 +
C18 125 + St18 235 +
C19 49.7 − St21 105 +
C20 58 − St22 66 −
C21 9 − St27 585 +
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sented in Table 1.
3.4. Plasma extracellular cytokine (HMGB1) level in ischemic stroke patients.
Relationship to clinical outcome and to cerebral infarction category
It was reported that serum HMGB1 levels, analyzed by Western
blotting, were signiﬁcantly elevated in both cerebral ischemia subjects
and in myocardial ischemia subjects [10]. Our results are based on the
estimation of plasma HMGB1 concentration by ELISA in ischemic stroke
subjects and in control subjects.
We have considered the plasma HMGB1 concentration in relation to
clinical outcome, and a correlation between increased HMGB1 concen-
tration and poor outcome has been observed. The data are presented
in Fig. 2C. The HMGB1 plasma concentration in each category of the
Oxfordshire Community Stroke Project classiﬁcation was compared
with the controls and this is presented in Fig. 2D. As follows from
Fig. 2D, total anterior circulation infarction (TACI) is signiﬁcantly corre-
lated with increased HMGB1 concentration in the plasma of IS patients.
3.5. The correlation betweenMMP-9 activation and levels of the extracellular
cytokine HMGB1 at acute ischemic stroke
Our data conﬁrm that activated MMP-9 can be considered a good
marker for a poor outcome (GOS) at IS within the early phase of ische-
mic stroke development. As follows from the above results, increased
HMGB1 can be also considered as a marker for poor outcome (GOS) at
IS within the ﬁrst 24 h of ischemic stroke development. This is why
we have examined the links between MMP-9 and HMGB1 levels for
the different functional outcomes according to GOS classiﬁcation. In pa-
tients with ischemic stroke the increased plasma MMP-9 and HMGB1
levels are associated with a poor functional outcome and signiﬁcantly
correlated with each other (P b 0.05). The results are presented in the
Fig. 3A. In case of a fairly good functional outcome (Fig. 3B), no correla-
tion has been observed betweenMMP-9 andHMGB1 levels in plasma (P
N 0.05).
3.6. MMP-12 in plasma at ischemic stroke
MMP-12 is expressed in alveolar macrophages. The mean MMP-12
concentration in the plasma of healthy subjects is 1.2 pg/ml. A commer-
cially availablemultiplex beads immunoassay has beenused to estimate
plasma MMP-12 concentrations in moyamoya disease patients and in
controls [11]. It was shown that even using this immunoassay, MMP-
12 content in controls is out of range of detection but is detectable in
moyamoya disease patients at ~9 pg/ml. We used Western blotting
with anti-MMP-12 antibodies for the examination of plasma MMP-12in ischemic stroke patients. MMP-12 is characterized by a MW 60 kDa
(zymogenic form) and a set of active forms having MWs ranging from
50/45 to 25 kDa can be observed as the result of auto-proteolytic activity
(Fig. 4). The main upper band corresponds to molecular weight (MW)
45 kDa, and there are several lines under it with the minimum at MW
25 kDA. The MMP-12 zymogenic form is not detectable in the plasma
samples, consistent with the high auto-proteolytic properties of MMP-
12.
Another important feature of MMP-12 is its ability to activate other
MMPs in vivo [12]. To ﬁnd out if the MMP-9 in IS samples is activated
by MMP-12, the IS samples characterized by the prominent MMP-9
active form (IS17, IS7, IS11) and the control samples, characterized by
low levels of MMP-9 active form (C6, C7, C16), have been analyzed
for their MMP-12 quantity (Fig. 4). The intensity of the main band
(45 kDa) for the studied samples was very similar, which points to an
equal quantity of MMP-12 in plasma for both types of samples. There-
fore, we can conclude that MMP-9 activation at acute ischemic stroke
is not the result of MMP-12 action.
4. Discussion
MMPs can degrade many matrix components; however, under
normal physiological conditions their proteolytic enzyme activities are
strictly controlled via gene expression, proenzyme activation and inhi-
bition by tissue inhibitors of metalloproteinases and enzyme degrada-
tion [13]. In pathological conditions this equilibrium can be shifted
towards increased MMP activity leading to tissue and extracellular ma-
trix degradation [14]. Among early serological markers of substantial
brain insult and poor outcome, MMPs deserve much attention since a
growing body of evidence points to their key role in the ischemic
cascade. The activation ofMMPs has been implicated as a negative prog-
nostic factor in human stroke because MMPs are able to cleave type IV
collagen, laminin and ﬁbronectin, the major components of the basal
lamina around cerebral blood vessels. Plasma MMP-9 concentration
was identiﬁed as a predictor of cardiovascular mortality in patients
with coronary artery disease [15]. A strong correlation was also found
between MMP-9 and MMP-13 with diffusion-weighted image (DWI)
lesion expansion in cases of acute ischemic stroke [16]. Other clinical
studies have shown that MMP-9 expression in acute cardioembolic
stroke is related to hemorrhagic transformation, whereas its levels are
associated with neurological deﬁcit, middle cerebral artery occlusion
and infarct volume [17,18]. The elevated level of MMP-9mRNA is a pre-
dictor of poor outcome and mortality in stroke [19].
In the present study, the increased level of MMP-9 after acute IS is
observed, and the strong correlation between increased plasma MMP-
9 concentration and MMP-9 activation was noted for IS patients. The
activated MMP-9 can be considered as an effective marker for negative
HMGB1 vs. MMP-9
(1 to 3) GOS
HMGB1 vs. MMP-9
(4 & 5) GOS
A B
Fig. 3. Correlations between the levels of plasma HMGB1andMMP-9 in IS patients with different functional outcomes. Correlations were determined by combining data from 42 patients
using Spearman and Pearson rank correlation analysis. (A) IS (1 to 3)—Poor outcome (Spearman r= 0.71, P= 0.046; Pearson r= 0.86, P= 0.0054). (B) IS (4 and 5)—Favorable outcome
(Spearman r = 0.037, P = 0.85; Pearson r =−0.13, P = 0.52).
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ment. Additionally, IS pathophysiology classiﬁcation of the patients in
accord with OCSP revealed that MMP-9 concentration increased only
in the plasma of patients with total anterior circulation infarction.
The plasma HMGB1 level is considered as an independent predictor
of long-term clinical outcomes of IS [20]. An increase in plasma
HMGB1concentration, persisting for 30 days, is associated with stroke
[21]. In the present study, the increased level of plasma HMGB1 after
acute IS is observed within 24 h of stroke onset, and the correlation be-
tween increased HMGB1 concentrations and IS outcome has been
detected.
It is well known that the use of a combination of several different
markers may help to minimize the variability of any individual marker.
For this reason we made the ﬁrst study of the relation between MMP-9
and the proinﬂammatory cytokine HMGB1 following acute IS. A strong
correlation was detected between increased MMP-9 and HMGB1 levels
andwith a poor outcome (death or functional decline). A possible cause
of the synchronized increase of plasmaMMP-9 andHMGB1 levels could
be secretion from neutrophils, as MMP-9 is a neutrophil-derived blood
MMP and a high quantity of HMGB1 characterizes these blood cells.
HMGB1 can be actively released from neutrophils in response to devel-
opment of prooxidant and proinﬂammatory conditions that develop at
IS [22]. The inﬂammatory activity of HMGB1 is dependent upon theMMP-12  WESTERN
100 kDa
60 kDa
45 kDa
30 kDa
20 kDa
M            IS17     IS7  IS11
MMP-9 ng/ml 535 172 428
Fig. 4.Western blot, stainedwith anti-MMP-12, demonstrating the samequantity ofMMP-12 in
12 in plasma samples. MMP-12 pro-enzymewas used as a standard. The ColorBurst electropho
marker; St—MMP-12 pro-enzyme.oxidation status of cysteine 106 residing within the B box, a region
that is critical for stimulating cytokine release and inﬂammation [23].
Mechanisms upregulating MMP expression remain largely unknown
but numerous studies now suggest that reactive oxygen species also
regulate MMP activity [24,25].Acknowledgments
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